2018 International Congress Archives - Page 34 of 177

1:15pm-2:45pm: Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Cerebrospinal Fluid C-Reactive Protein

H. Sanjari Moghaddam, M.H. Aarabi (Tehran, Islamic Republic of Iran)

Parkinson's Disease: Pathophysiology · Hall 3FG

1:15pm-2:45pm: Multi-echo GRE and DTI MR imaging of the Substantia Nigra in early Parkinson’s disease: A pilot 1-year prospective controlled study

T. Mestre, G. Melkus, G. Santos, D. Grimes, S. Chakraborty (Ottawa, ON, Canada)

Parkinson's Disease: Neuroimaging And Neurophysiology · Hall 3FG

1:15pm-2:45pm: Multi-limb dual-task cost in Parkinson disease: Evaluating effects of implicit and explicit cues

T. McIsaac, R. Cohen, R. Bay, J. Gupta, C. Adler (Mesa, AZ, USA)

Parkinson's Disease: Cognition · Hall 3FG

1:15pm-2:45pm: Multimorbidity predicts quality of life but not motor severity in early Parkinson’s disease

R. Gravell, G. Duncan, T. Khoo, D. Burn, A. Sayer, R. Barker, R. Lawson, A. Yarnall (Newcastle upon Tyne, United Kingdom)

Parkinson's Disease: Non-Motor Symptoms · Hall 3FG

1:15pm-2:45pm: Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

L. Chahine, T. Beach, C. Coffey, C. Caspell-Garcia, C. Alder, G. Serrano, S. Mosovsky, T. Foroud, C. Linder, H. Riss, D. Ecklund, J. Seibyl, A. Mallya, V. Arnedo, L. Riley, K. Dave, D. Jennings, B. Mollenhauer (Pittsburgh, PA, USA)

Parkinson's Disease: Pathophysiology · Hall 3FG

1:15pm-2:45pm: Nanoscale imaging reveals disorganization of the brain extracellular space in Lewy body-injected mice

F. Soria, N. Danne, C. Paviolo, E. Doudnikoff, B. Dehay, L. Groc, L. Cognet, E. Bezard (Bordeaux, France)

Parkinson's Disease: Pathophysiology · Hall 3FG

1:15pm-2:45pm: Natural history of RBD in Parkinson´s disease and response to dopaminergic and non-dopaminergic antiparkinsonian treatment

M. Ruiz-Lopez, V. Bruno, ME. Freitas, R. Rajalingam, A. Chang, S. Fox, A. Lang (Toronto, ON, Canada)

Parkinson's Disease: Non-Motor Symptoms · Hall 3FG

1:15pm-2:45pm: Natural occurring antibodies reduce aggregation of α-synuclein

A. Braczynski, E. Agerschou, Y. Kronimus, W. Hoyer, R. Dodel, B. Falkenburger, J. Schulz, J. Bach (Aachen, Germany)

Parkinson's Disease: Pathophysiology · Hall 3FG

1:15pm-2:45pm: Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD

M. Matarazzo, P. Martínez Martín, J.C. Martínez-Ávila, A. Gómez de-la-Cámara, L. Giancardo, T. Arroyo Gallego, P. Montero Escribano, V. Puertas-Martín, I. Obeso, I. Butterworth, C.S. Mendoza, M.J. Catalán, J.A. Molina-Arjona, F. Bermejo-Pareja, J.C. Martínez-Castrillo, L. López-Manzanares, A. Alonso-Canovas, J. Herreros-Rodríguez, M. Gray, Á. Sánchez-Ferro (Vancouver, BC, Canada)

Rating Scales · Hall 3FG

1:15pm-2:45pm: Neurocognitive outcomes of STN-DBS in patients with Parkinson’s disease: A 10-year review of local experiences in Hong Kong

V. Tang, X.L. Zhu, D. Chan, C. Lau, A. Chan, V. Mok, J. Yeung, W.S. Poon (Hong Kong)

Parkinson's Disease: Cognition · Hall 3FG